Progressive Americans raise concerns over possible cuts in reconciliation bill – LIVE















Biden attends US-ASEAN summit skipped by Trump















The Food and Drug Administration advisory panel will discuss the Pfizer-BioNTech vaccine itself. The recommended dosage for children is 10 micrograms, or one-third of the adult dose of Pfizer-BioEntech vaccine.

Moderna released on Monday promising early results for its vaccine in children aged six to 11 years, but this trial is still ongoing.

Given all the scientific evidence, the advisor will make recommendations to the FDA on this reduced dose of the Pfizer-BioNTech vaccine. While the FDA is not required to follow advisors’ recommendations, the agency usually does.

If advisers from the US Centers for Disease Control and Prevention (CDC) also recommend a vaccine at next week’s meeting, it will quickly rolled over For children aged five and older across the country, the outbreak marks a significant development in America’s response to the coronavirus.

Last week, nearly 118,000 children tested positive for Covid, taking the total to more than 1 million new cases among children in the past six weeks. According For the American Academy of Pediatrics. At least 584 US children have died from Covid.

In addition to protecting children from Covid-19 and its long-term effects, vaccination can also help protect those around them.

“We will not be able to get out of this pandemic without vaccinating children – both for our own sake and for our overall safety,” said Dr. Saad Omar, infectious disease epidemiologist and director of the Yale Institute for Global Health. said The Guardian earlier this month.








FDA weighs coronavirus vaccine for children ages five to 11

Today, US Food and Drug Administration (FDA) advisors will consider Pfizer-BioNtech’s application for its Covid-19 vaccine for children aged five to 11.

If it is authorized, it would be the first vaccine available for young children in the US.

The advisory committee will discuss the vaccine’s effectiveness and potential risk of side effects such as myocarditis, a type of heart inflammation, before making a recommendation to the regulatory agency at the end of the day.

Pfizer-BioNtech figures released on Friday show the vaccine is 90.7% effective To prevent symptomatic disease among this age group.

Vaccination benefits “clearly outweigh” risks of myocarditis and pericarditis, FDA scientists conclude Analysis Also made public on Friday.








Progressives raise concerns about possible reconciliation deal with Munchkin

.